Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

Relypsa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Relypsa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Relypsa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Relypsa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Relypsa Inc (Relypsa), a subsidiary of Vifor Pharma AG is a biopharmaceutical company that discovers, develops and commercializes polymeric medicines. The company's lead product candidate includes veltassa, a potassium binder approved for the treatment of hyperkalemia. It develops other polymer-based medicines for gastrointestinal diseases, or disorders associated with mineral ion imbalance, high levels of bacterially produced toxins, diabetes and inflammation, and others. Relypsa provides polymer technology that addresses many health conditions in need of viable treatment. Its veltassa treats hyperkalemia. Relypsa is headquartered in Redwood City, California, the US.

Relypsa Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Relypsa Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Relypsa Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Relypsa Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Relypsa Secures USD2.6 Million in Venture Funding 10

Relypsa Raises USD 80 Million In Series C Financing 11

Relypsa Secures USD62.4 Million in Venture Funding 13

Partnerships 14

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 14

Equity Offering 15

Relypsa Raises USD172 Million in Public Offering of Shares 15

Relypsa Completes Public Offering Of Shares For USD 101.2 Million 17

Relypsa Completes IPO For USD 86.7 Million 19

Acquisition 21

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 21

Relypsa May Sell Itself 23

Relypsa Inc-Key Competitors 24

Relypsa Inc-Key Employees 25

Relypsa Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Government and Public Interest 27

Apr 16, 2018: Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders 27

Product News 28

11/03/2017: Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa at ASN Kidney Week 2017 28

07/21/2017: European Commission Approves Marketing Authorisation For Veltassa 29

05/19/2017: CHMP Recommends Veltassa For The Treatment Of Hyperkalaemia In The EU 30

05/08/2018: US FDA Approves Use of Veltassa with or without Food 31

04/19/2017: Relypsa Presents Veltassa Phase 4 Data Showing Consistent Efficacy and Safety Whether Taken With or Without Food in Patients with Hyperkalemia 32

01/04/2018: Vifor Pharmas Veltassa Approved for Marketing in Switzerland for the Treatment of Hyperkalaemia 33

Clinical Trials 34

Apr 11, 2018: Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings 34

Feb 13, 2017: Relypsa Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Relypsa Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Relypsa Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Relypsa Inc, Pharmaceuticals & Healthcare, Key Facts 2

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Relypsa Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Relypsa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Relypsa Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Relypsa Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Relypsa Secures USD2.6 Million in Venture Funding 10

Relypsa Raises USD 80 Million In Series C Financing 11

Relypsa Secures USD62.4 Million in Venture Funding 13

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 14

Relypsa Raises USD172 Million in Public Offering of Shares 15

Relypsa Completes Public Offering Of Shares For USD 101.2 Million 17

Relypsa Completes IPO For USD 86.7 Million 19

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 21

Relypsa May Sell Itself 23

Relypsa Inc, Key Competitors 24

Relypsa Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Relypsa Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person